EXACT Sciences Board of Directors Rejects Acquisition Proposal from Sequenom, Inc.

MARLBOROUGH, Mass.--(Business Wire)--
EXACT Sciences Corporation (NASDAQ: EXAS) announced that its Board of Directors
has unanimously rejected an acquisition proposal by Sequenom, Inc. (NASDAQ:
SQNM) to acquire EXACT for $1.50 per share in Sequenom common stock, subject to
a collar.

The Board, after reviewing the proposal with its financial and legal advisors,
has determined to reject the proposal. The Company is actively pursuing a
strategic alternative that the Board believes can provide greater value to EXACT
and its shareholders than the Sequenom proposal.

About EXACT Sciences Corporation

EXACT Sciences Corporation uses applied genomics to develop patient-friendly
screening technologies for use in the detection of cancer. EXACT maintains an
exclusive license agreement in the United States and Canada with Laboratory
Corporation of America Holdings (LabCorp) for certain intellectual property
relating to stool-based DNA screening. EXACT continues to retain rights to offer
a colorectal cancer testing service itself within the United States, to develop
a U.S. Food and Drug Administration cleared or approved in vitro diagnostic
colorectal cancer test kit, and rights to license its colorectal cancer
technologies outside of the United States and Canada. Stool-based DNA technology
is included in the colorectal cancer screening guidelines of the American Cancer
Society and the U.S. Multi-Society Task Force on Colorectal Cancer (a group
comprised of representatives from the American College of Gastroenterology,
American Gastroenterological Association, and American Society for
Gastrointestinal Endoscopy), and the American College of Radiology. The Company
has 115 patents in the United States and abroad, with key intellectual property
assets applicable to the field of oncology and reproductive health. EXACT
Sciences is based in Marlborough, Mass.

Certain statements made in this press release that are not based on historical
information are express or implied forward-looking statements relating to, among
other things, EXACT Sciences' expectations concerning its long-term potential
and similar matters. These statements are neither promises nor guarantees, but
are subject to a variety of risks and uncertainties, many of which are beyond
EXACT Sciences' control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other things, EXACT
Sciences' ability to secure FDA approval or clearance for any of its products;
changes in FDA guidance or policy; the ability to attract prospective
collaborators or other parties to enter into a collaboration, acquisition or
other strategic transaction with EXACT; the ability to raise additional capital
on acceptable terms; the clinical performance and market acceptance of its
technologies; the reproducibility of its research results in subsequent studies
and in clinical practice; sufficient investment in the sales and marketing of
EXACT Sciences' technologies; the success of its strategic relationship with
LabCorp; EXACT Sciences' ability to license certain technologies or obtain raw
materials for its technologies; the ability to convince Medicare and other
third-party payors to provide adequate reimbursement for EXACT Sciences'
technologies; the ability to convince medical practitioners to order tests using
EXACT Sciences' technologies; the ability to increase the performance its
technologies; the ability of EXACT Sciences or LabCorp to lower the cost of
stool-based DNA screening technologies through automating and simplifying key
operational processes; the number of people who decide to be screened for
colorectal cancer using EXACT Sciences' technologies; competition; the ability
to protect EXACT Sciences' intellectual property and the cost of enforcing or
defending EXACT Sciences in litigation relating to intellectual property rights;
and the possibility that other companies will develop and market novel or
improved methods for detecting colorectal cancer. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. EXACT Sciences undertakes no
obligation to update or revise the information contained in this press release,
whether as a result of new information, future events or circumstances or
otherwise and specifically disclaims any obligation to provide updated
information concerning the potential strategic alternatives that it is actively
pursuing. For additional disclosure regarding these and other risks faced by
EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings
with the Securities and Exchange Commission including, without limitation, its
most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form
10-Q filed with the SEC.

Westwicke Partners, LLC
John Woolford, 443-213-0506
john.woolford@westwickepartners.com

Copyright Business Wire 2009